Opinion: Hold CEO's Accountable
by Paul Thacker for New Scientist
THERE have been so many stories about pharmaceutical companies promoting the misuse or abuse of their drugs that the names seem to merge - Zyprexa, Seroquel, Paxil and more.
The latest case concerns GlaxoSmithKline's Avandia (rosiglitazone), an anti-diabetes drug linked to heart attacks. Last month, the European Medicines Agency recommended its suspension from the market, while the US Food and Drug Administration made it all but impossible for doctors to write prescriptions for the drug.
With sales worth over $3 billion in 2006, Avandia was the world's best-selling diabetes drug until May 2007, when The New England Journal of Medicine published a study linking it to heart attacks. Reporters circled, and the finance committee of the US Senate investigated, forcing GSK to hand over internal documents.